Patents by Inventor Peter M. SZABO

Peter M. SZABO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MULTI-TUMOR GENE SIGNATURE FOR SUITABILITY TO IMMUNO-ONCOLOGY THERAPY
    Publication number: 20220363760
    Abstract: The present disclosure provides methods of identifying a subject suitable for an immunooncology (I-O) therapy comprising measuring the expression of one or more genes of a pantumor inflammation gene panel. In some aspects, the method further comprises administering an I-O therapy to the subject. In some aspects, the I-O therapy comprises administering an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof to the subject.
    Type: Application
    Filed: May 29, 2020
    Publication date: November 17, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventors: Peter M. SZABO, Lan ZHANG, Keyur H. DESAI, Neeraj ADYA, Zhenhao QI, Kim ZERBA, Scott Adams ELY, Saumya PANT, George A. GREEN
  • ANTI-PD-1 ANTIBODY FOR USE IN A METHOD OF TREATING A TUMOR
    Publication number: 20220315657
    Abstract: This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, the tumor is derived from a non-small cell lung cancer (NSCLC). In some embodiments, the tumor expresses Programmed Death Ligand 1 (PD-L1), Serine/Threonine Kinase 11 (STK11), or both PD-L1 and STK11.
    Type: Application
    Filed: March 21, 2022
    Publication date: October 6, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventors: Robin EDWARDS, Han CHANG, Michele CLEARY, Peter M. SZABO, Joseph Daniel SZUSTAKOWSKI, Patrik VITAZKA
  • METHODS OF IDENTIFYING A SUBJECT SUITABLE FOR AN IMMUNO-ONCOLOGY (I-O) THERAPY
    Publication number: 20220259669
    Abstract: The present disclosure provides methods of identifying a subject suitable for an immunooncology (I-O) therapy comprising measuring the expression of one or more of STAT1, IFN?, NECTIN2, and CSFIR. In some aspects, the I-O therapy comprises administering an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof to the subject.
    Type: Application
    Filed: May 29, 2020
    Publication date: August 18, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventors: Peter M. SZABO, Lan ZHANG, Keyur H. DESAI, Neeraj ADYA, Zhenhao QI, Alex GREENFIELD, George C. LEE, Scott Adams ELY, Saumya PANT, George A. GREEN
  • METHODS OF TREATING TUMOR
    Publication number: 20220195046
    Abstract: The disclosure provides a method for treating a subject afflicted with a tumor comprising administering to the subject a therapeutically effective amount of an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or anti-gen-binding portion thereof, wherein the subject is identified as having a high inflammatory gene signature score and a tumor that has a high tumor mutation burden (TMB) status. In some embodiments, the high inflammatory gene signature score is determined by measuring the expression of a panel of inflammatory genes in a tumor sample obtained from the subject, wherein the inflammatory gene panel comprises CD274 (PD-L1), CD8A, LAG3, and STAT1.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 23, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventors: Ming LEI, Nathan O. SIEMERS, Dimple PANDYA, Han CHANG, Teresa K. SANCHEZ, Christopher T. HARBISON, Peter M. SZABO, Zachary S. BOYD, Xiaozhong QIAN, Samy Abdel SACI, Tina C. YOUNG, Sujaya SRINIVASAN, Megan M. WIND-ROTOLO, Jasmine RIZZO, Donald G. JACKSON, Alice M. WALSH
  • METHODS OF TREATING TUMOR
    Publication number: 20220041733
    Abstract: The disclosure provides a method for treating a subject afflicted with a tumor comprising administering to the subject a therapeutically effective amount of an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof, wherein the subject is identified as having a high inflammatory gene signature score. In some embodiments, the high inflammatory gene signature score is determined by measuring the expression of a panel of inflammatory genes in a tumor sample obtained from the subject, wherein the inflammatory gene panel comprises CD274 (PD-L1), CD8A, LAG3, and STAT1.
    Type: Application
    Filed: March 27, 2020
    Publication date: February 10, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventors: Ming LEI, Nathan O. SIEMERS, Dimple PANDYA, Han CHANG, Teresa K. SANCHEZ, Christopher T. HARBISON, Peter M. SZABO, Zachary S. BOYD, Alice M. WALSH
  • ANTI-PD-1 ANTIBODY FOR USE IN A METHOD OF TREATING A TUMOR
    Publication number: 20200325226
    Abstract: This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, the tumor is derived from a non-small cell lung cancer (NSCLC). In some embodiments, the tumor expresses Programmed Death Ligand 1 (PD-L1), Serine/Threonine Kinase 11 (STK11), or both PD-L1 and STK11.
    Type: Application
    Filed: June 2, 2017
    Publication date: October 15, 2020
    Applicant: Bristol-Myers Squibb Company
    Inventors: Robin EDWARDS, Han CHANG, Michele CLEARY, Peter M. SZABO, Joseph D. SZUSTAKOWSKI, Patrik VITAZKA